Share-Based Compensation (Tables)
|
3 Months Ended |
12 Months Ended |
Mar. 31, 2025 |
Dec. 31, 2024 |
| Share-Based Compensation [Abstract] |
|
|
| Schedule of Company’s Stock Option Activity |
The summary of the Company’s stock option
activity is as follows:
| | | Number of Stock Options | | | Weighted-
Average Exercise Price | | | Weighted-
Average Remaining Contractual Life | | | Outstanding at December 31, 2024 | | | 9,881,842 | | | $ | 1.71 | | | | 5.4 | | | Granted | | | — | | | | — | | | | — | | | Exercised | | | — | | | | — | | | | — | | | Forfeited/Expired/Cancelled | | | (2,929,108 | ) | | $ | 1.66 | | | | — | | | Outstanding at March 31, 2025 | | | 6,952,734 | | | $ | 1.73 | | | | 4.9 | | | Exercisable at March 31, 2025 | | | 5,758,095 | | | $ | 1.74 | | | | 5.0 | |
|
The summary of the Company’s
stock option activity is as follows:
| | | Number of
Stock
Options | | | Weighted-
Average
Exercise
Price | | | Weighted-
Average
Remaining
Contractual
Life | | | Outstanding at December 31, 2023 | | | 11,072,767 | | | $ | 1.64 | | | | 6.1 | | | Granted | | | - | | | | - | | | | - | | | Exercised | | | - | | | | - | | | | - | | | Forfeited/Expired/Cancelled | | | (1,190,925 | ) | | $ | 1.01 | | | | - | | | Outstanding at December 31, 2024 | | | 9,881,842 | | | $ | 1.71 | | | | 5.4 | | | Exercisable at December 31, 2024 | | | 8,281,791 | | | $ | 1.71 | | | | 5.4 | |
|
| Schedule of Company’s Restricted Stock Unit Activity |
The summary of the Company’s restricted
stock unit activity is as follows:
| | | | Number
of
Shares | | | Weighted-
Average
Grant Date
Fair Value | | | Weighted-
Average
Remaining
Vesting Period | | | Outstanding at December 31, 2024 | | | | 22,156 | | | $ | 1.63 | | | | 0.2 | | | Granted | | | | — | | | | — | | | | — | | | Vested | | | | (16,617 | ) | | | 1.63 | | | | — | | | Forfeited | | | | — | | | | — | | | | — | | | Outstanding at March 31, 2025 | | | | 5,539 | | | $ | 1.63 | | | | — | |
|
The summary
of the Company’s restricted stock unit activity is as follows:
| | | Number of
Shares | | | Weighted-
Average
Grant Date
Fair Value | | | Weighted-
Average
Remaining
Vesting Period | | | Outstanding at December 31, 2023 | | | 93,728 | | | $ | 1.63 | | | | 1.2 | | | Granted | | | - | | | | - | | | | - | | | Vested | | | (71,571 | ) | | | 1.63 | | | | - | | | Forfeited | | | - | | | | - | | | | - | | | Outstanding at December 31, 2024 | | | 22,156 | | | $ | 1.63 | | | | 0.2 | |
|
| Schedule of Recorded Stock-Based Compensation Expense |
The summary of the recorded stock-based compensation
expense is as follows:
| |
|
Three months ended March 31, |
|
| |
|
2025 |
|
|
2024 |
|
| |
|
|
|
|
|
|
| Research and development |
|
$ |
10 |
|
|
$ |
26 |
|
| General and administrative |
|
|
502 |
|
|
|
537 |
|
| Total stock-based compensation |
|
$ |
512 |
|
|
$ |
563 |
|
|
The summary of the recorded stock-based
compensation expense is as follows:
| | |
Years ended December 31, | |
| | |
2024 | | |
2023 | |
| | |
| | |
| |
| Research and development | |
$ | 72 | | |
$ | 118 | |
| General and administrative | |
| 1,855 | | |
| 2,187 | |
| Total stock-based compensation | |
$ | 1,927 | | |
$ | 2,305 | |
|
| Schedule of Fair Value Assumptions of the Stock Options Granted to Employees, Directors and Nonemployees |
|
The assumptions that the Company used
to determine the fair value of the stock options granted to employees, directors and nonemployees were as follows:
| | | Year ended
December 31,
2023 | | | Risk-free interest rate | | | 3.53 | % | | Expected term (in years) | | | 6.3 | | | Expected volatility | | | 71 | % | | Expected dividend yield | | | 0 | % |
|